ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

 After the HIV virus enters the human body, it first destroys the immune system, leading to a rapid decline in immunity. Consequently, the body becomes more susceptible to various infections and complications, the most common of which are infections in different systems and malignant tumors. As the life expectancy of people living with HIV (PLWH) increases, cases of coexisting malignant tumors are also on the rise. From September 7-9, 2023, the seventeenth International Liver Cancer Association (ILCA) annual meeting (ILCA 2023) was grandly held in Amsterdam, the capital of the Netherlands. At this conference, Dr. Eleonora Alimenti from the University of Pavia, Italy, orally presented the clinical features, treatment status, and clinical outcomes of PLWH coexisting with HCC at Lombardy's Third Hospital in Italy (Conference Abstract: O-07), drawing significant attention.